HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors

Farbod Shojaei; Bob Goodenow; Gloria Lee; Fairooz Kabbinavar; Mireille Gillings

doi:10.3389/fonc.2021.768685

HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors

Front Oncol. 2022 Jan 7:11:768685. doi: 10.3389/fonc.2021.768685. eCollection 2021.

Authors

Farbod Shojaei¹, Bob Goodenow¹, Gloria Lee¹, Fairooz Kabbinavar¹, Mireille Gillings¹

Affiliation

¹ HUYABIO International LLC, San Diego, CA, United States.

Abstract

HBI-8000 is a small molecule inhibitor of class I HDACs and has been approved for the treatment of PTCL, ATL and, in combination with exemestane, in a subpopulation of breast cancer. Given the roles of HDACs in normal and cancerous cells, there are currently multiple clinical trials, by HUYABIO International, to test the efficacy of HBI-8000 in monotherapy or in combination settings in leukemias and in solid tumors. The current review is focused on the applications of HDACi HBI-8000 in cancer therapy and its potential in combination with DDR agents.

Keywords: HBI-8000; HDACs; MOA; clinical; oncology; tumor immunology.

Publication types

Review